Bristol Myers uncorks positive PhIII readout for subcutaneous Opdivo

Bris­tol My­ers Squibb’s sub­cu­ta­neous for­mu­la­tion of its can­cer block­buster Op­di­vo proved non­in­fe­ri­or to in­tra­venous Op­di­vo in a Phase III tri­al, the com­pa­ny an­nounced on Thurs­day.

The study test­ed sub­cu­ta­neous Op­di­vo (nivolum­ab) in an open-la­bel tri­al for pa­tients with clear cell re­nal cell car­ci­no­ma (ccR­CC), though CMO Samit Hi­rawat has ex­pressed in­ter­est in ap­ply­ing the da­ta “to all oth­er in­di­ca­tions where Op­di­vo is used to­day as a sin­gle agent,” ac­cord­ing to an Al­phaSense tran­script of the com­pa­ny’s first-quar­ter earn­ings call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.